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ranscatheter Closure of
atent Foramen Ovale
or Migraine Prophylaxis
ope or Hype?*
otirios Tsimikas, MD, FACC
an Diego, California
“But the quality which is considered of the highest order in
surgical operations is self-possession. The head must always
direct the hand, otherwise the operator is unfit to discover an
effectual remedy. . . .”
—Sir Astley Cooper, Operating Theatre, St. Thomas’
Hospital, London (Lancet, October 5, 1823)
igraine has generally been conceptualized as a primary
isorder of the brainstem that mediates sensory input and
eural influences on cranial vessels. It is estimated that
,500,000 patients in the U.S. have at least one migraine per
eek, with a lifetime prevalence of 18%. Migraine is a risk
actor for cryptogenic stroke, particularly in young patients
ithout atherosclerosis risk factors. In fact, the prevalence of
ubclinical lesions in the cerebellum in patients with mi-
raine with aura, particularly women, is up to 15-fold higher
han controls (1). However, the underlying pathophysiology
f migraine is not well understood, and new paradigms in
nderstanding the underlying etiology and optimizing ther-
py are being explored.
See pages 489 and 493
The foramen ovale is composed of the septum primum
left atrial side, fenestrated cranially) and the septum secun-
um (right atrial side, fenestrated caudally) joined in parallel
orming a slit-like valve that shunts oxygenated blood to the
ystemic circulation during fetal development. A patent
oramen ovale (PFO) results from lack of normal closure
ostnatally. Atrial septal defects (ASD) and PFO are
resent in approximately 25% of patients at autopsy and
5% of patients with cryptogenic stroke (2,3). An underly-
ng mechanism of stroke in such patients includes transient
ight-to-left shunt during the release phase of Valsalva with
assage of venous microemboli systemically (i.e., paradoxic
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily reflect the views of JACC or the Americant
ollege of Cardiology.
From the University of California, San Diego, San Diego, California.mbolism). It is estimated that 70,000 strokes are associated
ith PFO annually in the U.S. (2).
In this issue of the Journal, two reports suggest an
ntriguing association between ASD/PFO closure and re-
uction in the incidence or even cure of migraine, particu-
arly migraine associated with aura. Azarbal et al. (4)
etrospectively evaluated changes in migraine patterns in 89
atients with cryptogenic stroke following ASD/PFO clo-
ure and showed a 42% migraine prevalence, with 62%
aving migraine with aura. At one-year follow-up, there
as complete resolution of migraine, starting immediately
ostprocedure, in 60% of patients (75% in those with aura),
nd improvement in the remaining 40%. Reisman et al. (5),
n a study of similar methodology, treated 162 patients with
resumed paradoxic embolism and showed a 35% preva-
ence of migraine, with 68% having migraine with aura.
omplete resolution of migraine was noted in 56% and
ignificant improvement in 14%. In both groups, clopi-
ogrel was given for three months and aspirin for at least six
onths postprocedure, and neurologists were involved in
he design and/or interpretation of the studies. These two
tudies corroborate several recent studies showing similar
esults, with enhanced improvement in patients with mi-
raine with aura (6–9) (Table 1).
Is there a plausible pathophysiologic link between ASD/
FO closure and relief or cure of migraine?
he hope. In patients with migraine with aura the
revalence of PFO, particularly those associated with
ight-to-left shunt, is significantly increased and similar
o young patients with cryptogenic stroke, suggesting a
ommon biologic link (10,11). Interestingly, patients
ith aura develop hypoperfusion in the occipital cortex,
nd paradoxical emboli seem to have a predilection for
his area of the brain (12). The prevalence of PFO is
ncreased in divers with migraine with aura, and precip-
tation of migraine has been documented immediately
ollowing diving or after placement of PFO devices in
uch patients (9). Migraine with aura also has occurred
uring contrast bubble studies, suggesting a causal mech-
nism, in patients with PFO, of paradoxic microemboli-
ation of gas, thrombi, or vasoactive neuromediators that
re normally filtered and degraded by the lungs. Migraine
ith aura is associated with increased platelet hyperag-
regability and is also more prevalent in young women
ho smoke and use oral contraceptives (13). Patent
oramen ovale is also associated with transient global
mnesia, another condition thought to be mediated by
brupt dysfunction of the vertebrobasilar circulation (14).
onsistent with the hypothesis of paradoxic emboliza-
ion, both aspirin and warfarin have been purported to
ecrease the incidence of migraine (15,16).
he hype. First, in all six studies combined, only 205
atients with migraine were included, with limited
ollow-up. Second, the majority of studies are retrospec-
ive and all are nonrandomized. Third, the data, although
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February 15, 2005:496–8 Editorial Commentollected with well-validated measures, are based primar-
ly on subjective recall of headache frequency rather than
bjectively gathered data, such as a headache diary and
se of migraine medications. Fourth, patients and phy-
icians were not blinded and it is not unreasonable to
uspect that they were aware of the possibility of migraine
mprovement at the time of ASD/PFO device implanta-
ion. Fifth, a strong possibility exists for placebo effect,
hich can occur in 20% to 40% of subjects in any
herapeutic study. However, the majority of patients
ither had complete resolution or improvement, suggest-
ng additional mechanisms beyond placebo effect. Sixth,
ll patients were treated with clopidogrel and aspirin,
hich may have reduced migraine frequency (6). Seventh,
wo recent reports (17,18) have actually reported either
ew migraine with aura or transformation to daily occur-
ence following Amplatzer ASD closure (complete ASD
losure was present and thrombus was ruled out by
ransesophageal echocardiography), questioning the pro-
osed mechanism of migraine. Eighth, the completeness
f PFO closure does not seem to be associated with
igraine relief, which is disappointing from a pathophys-
ology perspective. Last, there is a small but real risk of
ignificant complications related to placement of PFO
evices (2).
These studies generate a strong rationale for further
nvestigation in understanding the pathophysiology and
reatment of migraine. However, before PFO closure can
e proposed for migraine, a healthy skepticism should be
n place, considering the high frequency of both migraine
nd PFO in the general population. It will be necessary to
btain definitive evidence with randomized controlled
rials and to define the appropriate clinical indications.
esign of such trials, which are already in the planning
tages, will require adequate sample size and extended
ollow-up; optimal medical therapy, including antiplate-
et and perhaps anticoagulation therapy; possibly an arm
ith a sham procedure; and blinding of follow-up phy-
icians and nurses. Optimal design of such trials to seek
n answer to the hypothesis that PFO closure can
able 1. Effect of PFO Closure Devices on Migraine Headache
Authors (Ref.) Year
Type of
Study
# of
Subjec
illshurst et al. (9) 2000 Retrospective 37
orandi et al. (6) 2003 Prospective 17
ost et al. (7) 2004 Retrospective 66
chwerzmann et al. (8) 2004 Retrospective 215
zarbal et al. (4) 2004 Retrospective 89
eisman et al. (5) 2004 Retrospective 162
otal 586
/A  not applicable; PFO  patent foramen ovale.meliorate migraine will enhance the concept of applyingvidence-based medicine in clinical decision-making that
he cardiovascular community has promulgated so well
ver the past three decades. In addition, such trials can
otentially lead to new paradigm shifts in the under-
tanding and treatment of migraine.
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